Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn's patients

Abstract

Abstract

Introduction

Limited knowledge exists as to what impact preoperative biologic therapy has on postoperative complications in pediatric patients undergoing abdominal surgery for Crohn's disease (CD). Therefore, we sought to determine the 30-day postoperative infectious complication rate among pediatric CD patients who received biologic therapy within 12 weeks of an abdominal operation.

Methods

A retrospective chart review was performed on pediatric (

This article is published on an external journal. Click below to read the full text.